Current Report Filing (8-k)
SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16,
(Exact name of
registrant as specified in its charter)
|(State or other jurisdiction
5403 Betsy Ross Drive
Santa Clara, California
|(Address of principal executive
Registrant’s telephone number, including area code: (510) 279-4262
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
||Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
||Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
||Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
||Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name of Each Exchange on Which
Common Stock, par value
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
||Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain
Compensatory Arrangements of Certain Officers.
On July 16, 2020, the Board of Directors (the “Board”) of Shockwave
Medical, Inc. (the “Company”), upon the recommendation of the
Board’s Nominating and Corporate Governance Committee, appointed
Ms. Maria Sainz as a Class I member of the Board, effective July
16, 2020, to fill a vacancy on the Board resulting from an increase
in the number of directors constituting the Board, to serve until
the Company’s 2023 Annual Meeting of Stockholders and her successor
is duly elected and qualified, or until her earlier death,
resignation, or removal. Ms. Sainz will serve on the Compensation
Committee of the Board.
Ms. Sainz has served as the President and CEO of AEGEA Medical,
Inc., since May of 2018. She has over 25 years’ experience in
commercial and leadership positions in the medtech industry. Ms.
Sainz previously served as the President & CEO of
Cardiokinetix, a medical device company pioneering a catheter-based
treatment for heart failure. Prior to that, Ms. Sainz was the
President & CEO of Concentric Medical, Inc., a developer of
minimally invasive products for the treatment of acute ischemic
stroke, which was acquired in 2011 by Stryker Corporation. Ms.
Sainz began her medtech career at Guidant Corporation where she
held positions of increasing responsibility in Europe and the US.
At the time of the acquisition of Guidant by Boston Scientific, Ms.
Sainz served as President of the Cardiac Surgery division of
Guidant Corporation. Ms. Sainz has been intimately involved in
several major medtech product launches such as coronary stents or
cardiac resynchronization therapy devices. Ms. Sainz also serves as
a Director of several public and private medical company boards.
She received a M.A in Languages from the University Complutense in
Madrid, Spain and a Masters in International Management from the
American Graduate School of International Management.
Ms. Sainz will receive compensation in accordance with the
Company’s standard compensatory arrangement for non-employee
directors in effect from time to time, as most recently described
under the caption titled “Director Compensation” in the Company’s
proxy statement filed with the Securities and Exchange Commission
on April 28, 2020. Ms. Sainz and the Company have entered into the
Company’s standard indemnification agreement for directors and
executive officers, the form of which was filed as Exhibit 10.7 to
the Company’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 12, 2020. There are no other
material plans, contracts or arrangements in which Ms. Sainz will
participate in connection with her appointment.
There are no arrangements or understandings between Ms. Sainz and
any other person pursuant to which Ms. Sainz was selected as a
director. Ms. Sainz has not been involved in any related person
transactions with the Company that would require disclosure under
Item 404(a) of Regulation S-K.
On July 20, 2020, the Company posted on its website a press release
announcing the appointment of Ms. Sainz to the Board. A copy of
that press release is attached hereto as Exhibit 99.1.
||Financial Statements and
Item 9.01(d) – Exhibits
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
||Shockwave Medical, Inc.
|Date: July 20, 2020
/s/ Hajime Tada
ShockWave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Aug 2020 to Sep 2020
ShockWave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Sep 2019 to Sep 2020